QS-21
- Generic Name
- QS-21
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 61H83WZX3U
- Background
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.
- Indication
Investigated for use/treatment in genital herpes, HIV infection, hepatitis (viral, B), influenza, malaria, melanoma, and viral infection.
NIH Study: Single Dose of MEDI8852 Antibody Shows Complete Protection Against H5N1 Avian Flu in Primates
• A groundbreaking NIH study demonstrates that a single dose of MEDI8852, a broadly neutralizing antibody developed by MedImmune/AstraZeneca, provides complete protection against H5N1 avian influenza in macaques.
• The antibody targets a stable portion of the influenza virus protein, offering extended protection that could last weeks after administration, making it a promising preventive tool for potential H5N1 outbreaks.
• All macaques pre-treated with MEDI8852 survived H5N1 exposure with minimal or no symptoms, while untreated control subjects developed severe or fatal illness.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath